Sabrina McCrear

Senu Apewokin, MD, explains why asymptomatic C diff carriage complicates care for transplant and chemotherapy patients excluded from trials.

Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling help.

Jordan Feld, MD, MPH, discusses bepirovirsen's approval and how capsid assembly modulators and gene editing could lead to a true hepatitis B cure.

Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.

Jordan Feld, MD, MPH, explains how HBsAg testing, NUC therapy, and monitoring capacity will shape access to hepatitis B functional cure.

Senu Apewokin, MD, explains why C diff in ICU and chemotherapy patients may reflect colonization, not hospital transmission.

Universal HCV testing, community-based prevention, and peer navigators can help curb a decade-long surge in new US hepatitis C cases.

Aditi Ramakrishnan, MD, MSc, explains how pharmacy benefit gaps and prior authorization denials keep patients from long-acting injectable PrEP.

The US has curative HCV treatment and rapid tests but lags peer nations in prevention for people who inject drugs.

Naima T. Joseph, MD, MPH, explains measles risks in pregnancy, atypical presentations, and the narrow window for prophylaxis.

Universal HCV testing in pregnancy, DAA therapy, and earlier infant RNA testing can curb mother-to-child hepatitis C transmission.

Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.

Immediate DAA treatment, syringe services, and society advocacy are key to eliminating the hepatitis C virus (HCV) among people who use drugs.

Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.

Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.

Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.

Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.

On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.

New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.

Michael Mina, MD, PhD, of Invivyd explains how a few amino acid changes let VYD2311 move from IV to a single IM shot that could expand access.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

Joanna Parga-Belinkie, MD, explains how framing VKDB as a stroke and documenting refusals helps her counsel parents on vitamin K.

Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.

Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.

Joanna Parga-Belinkie, MD, of CHOP explains how she tailors counseling to address vitamin K shot misinformation and VKDB risks.

Jaspreet Loyal, MD, MS, of Yale explains why vitamin K shot refusals are rising and how clinicians counsel hesitant parents in the newborn nursery.

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.